The success of allogeneic hematopoietic cell transplantation (HCT) is typically assessed as individual complications, including graft-versus-host disease (GVHD), relapse, or death, yet no one factor can completely characterize cure without ongoing morbidity. We examined a novel composite end point of GVHD-free/relapse-free survival (GRFS) in which events include grade 3-4 acute GVHD, systemic therapy-requiring chronicGVHD, relapse, or death in the first post-HCT year. In 907 consecutive University of Minnesota allogeneic HCT recipients (2000-2012), 1-year GRFS was 31% (95% confidence interval [CI] 28-34). Regression analyses showed age, disease risk, and donor type significantly influencing GRFS. Adults age 21+ had 2-fold worseGRFSvs children;GRFSdid not differ beyondage 21. Adjusted for conditioning intensity, stem cell source, disease risk, age, and transplant year, HLA-matched sibling donor marrow resulted in the best GRFS (51%, 95% CI 46-66), whereas HLA-matched sibling donor peripheral blood stem cells were significantly worse (25%, 95% CI 20-30, P = .01). GRFS after umbilical cord blood transplants and marrowfrommatched unrelated donors were similar (31%, 95% CI 27-35 and 32%, 95% CI 22-42, respectively). BecauseGRFSmeasures freedom fromongoingmorbidity and represents ideal HCT recovery, GRFS has value as a novel end point for benchmarking new therapies. (Blood. 2015;125(8):1333-1338)
Bibliographical notePublisher Copyright:
© 2015 by The American Society of Hematology.